Abstracts tagged "obesity"

Abstract Number: 1646 • ACR Convergence 2025
The Obesity Paradox in Rheumatoid Arthritis: A Propensity-Matched Analysis of Mortality and Cardiovascular Outcomes
Queeneth Edwards¹, Chukwuemelie Okeke², Justin Riley³, Ufuoma Mamoh⁴ and Chekwube Obianyo⁵, ¹Georgia Southern University, Statesboro, GA, ²Maimonides Medical Center, Brooklyn, NY, ³Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ⁴Medstar Health Georgetown University Internal Medicine Residency Program, Baltimore, MD, ⁵Georgia Southern University, statesboro
Background/Purpose: Obesity is traditionally associated with increased morbidity and mortality in the general population. However, in chronic inflammatory conditions like rheumatoid arthritis (RA), an "obesity…
Abstract Number: 1383 • ACR Convergence 2025
Obesity in Primary Sjogren’s Disease
Gabriela Hernandez-Molina¹, Donaji Gómez-Velasco², Ariel Garcia-Torralba², Carlos Aguilar-Salinas² and Ivette Cruz-Bautista², ¹Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Federal District, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Obesity is an excessive fat accumulation that presents a risk to health. Little is known about the relationship between obesity and Sjögren’s disease (SjD).…
Abstract Number: 1130 • ACR Convergence 2025
Novel Anti-Obesity Medications and Serum Urate Change Among Patients with Gout and Baseline Hyperuricemia
Kiara Tan¹, Jiaqi Wang¹, Saiajay Chigurupati², Gregory Challener³, Natalie McCormick¹, Sharan Rai⁴, Florence Porterfield⁵, Chika Anekwe¹, Dong Wook Kim⁶, Fatima Stanford⁷, Caroline Apovian⁸, Hyon K. Choi⁹ and Chio Yokose¹⁰, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ⁴Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁵Division of Endocrinology, Massachusetts General Hospital, Boston, ⁶Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital, Boston, ⁷Neuroendocrine Unit, Pediatric Endocrinology, Massachusetts General Hospital, Boston, ⁸Brigham and Women's Hospital, Boston, ⁹MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ¹⁰Massachusetts General Hospital, Waltham, MA
Background/Purpose: Obesity affects >50% of individuals with gout and is the most important modifiable risk factor for gout. Thus, novel anti-obesity medications (AOM, e.g., semaglutide…
Abstract Number: 1027 • ACR Convergence 2025
GLP-1 Receptor Agonists to Facilitate Weight Loss and Improve Disease Activity, Pain and Function in Patients With Rheumatic and Musculoskeletal Disease: Real-World Evidence From the Rheumatology Informatics System for Effectiveness (RISE) Registry
Nick McCormick¹, Jingyi Zhang², Emily Holladay², Fenglong Xie³ and Jeffrey Curtis⁴, ¹Auburn University, Auburn, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) such as semaglutide (SEM; GLP-1) and tirzepatide (TIR; GIP/GLP-1), were initially approved for type 2 diabetes management but…
Abstract Number: 1011 • ACR Convergence 2025
Model-based Evaluation of the Potential Public Health Impact of Expanding Medicare Coverage for Weight Loss Medications for Beneficiaries with Knee Osteoarthritis and Obesity in the US.
Ethan Eickmann¹, Daniel Betensky¹, Karen Smith¹, Candace Feldman¹, Jason Kim², Ankur Pandya³, Jeffrey Katz⁴ and Elena Losina⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Arthritis Foundation, Atlanta, GA, ³Harvard School of Public Health, Boston, ⁴Brigham and Women's Hospital, Brookline, MA, ⁵BWH, Boston, MA
Background/Purpose: US federal law currently does not allow Medicare Part D coverage for weight loss medications without additional indications, such as diabetes. Several glucagon-like peptide-1…
Abstract Number: 0813 • ACR Convergence 2025
Impact of Tirzepatide on Musculoskeletal Pain and High-Risk Analgesic Use Among Non-Diabetic Patients with Overweight or Obesity: A Propensity Score-Matched, Active Comparator, New User Study
Gregory Challener¹, Kevin Sheng-Kai Ma², Natalie McCormick³, Minna Kohler⁴, Janeth Yinh³, Chio Yokose⁵, Sharan Rai⁶, Florence Porterfield⁷, Fatima Stanford⁸, Dong Wook Kim⁹, April Jorge³ and Hyon K. Choi¹⁰, ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ²Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Philadelphia, PA, ³Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital, Waltham, MA, ⁶Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁷Division of Endocrinology, Massachusetts General Hospital, Boston, ⁸Neuroendocrine Unit, Pediatric Endocrinology, Massachusetts General Hospital, Boston, ⁹Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital, Boston, ¹⁰MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Tirzepatide is a dual GIP/GLP-1 receptor co-agonist approved for weight loss in patients with obesity or body mass index (BMI) > 27 kg/m2 with…
Abstract Number: 0438 • ACR Convergence 2025
Exploring the Potential for Cardiorenal-Metabolic Therapies to Target Comorbidities in Early Rheumatoid Arthritis
Bindee Kuriya¹, Susan J. Bartlett², Marie-France Valois³, Janet Pope⁴, Carter Thorne⁵, Carol Hitchon⁶, Hugues Allard-Chamard⁷, Glen Hazlewood⁸, Gilles Boire⁹, Louis Bessette¹⁰ and Vivian Bykerk¹¹, ¹Mount Sinai Health, Toronto, Canada, ²McGill University, Beaconsfield, QC, Canada, ³McGill University, Pointe-Claire, QC, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Centre of Arthritis Excellence, Newmarket, ON, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Université de Sherbrooke, Sherbrooke, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹Retired, Sherbrooke, QC, Canada, ¹⁰Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ¹¹Hospital for Special Surgery, New York, NY
Background/Purpose: Cardiorenal-metabolic (CRM) therapies, such as SGLT-2 inhibitors and GLP-1 agonists, are medications that target interconnected pathways between cardiovascular, renal, and metabolic systems and may…
Abstract Number: 2660 • ACR Convergence 2025
Understanding Gout in Women: Longitudinal Changes in Serum Urate Levels from Pre-menopause through Post-menopause
Shreya Billa¹, Sho Fukui¹, Misti Paudel², Takahiro Suzuki³, Ryosuke Imai⁴, Yuntae Kim⁵, Takehiro Nakai⁶, Hiromichi Tamaki⁶, mitsumasa kishimoto⁷, Hilde Ørbo¹, Sara Tedeschi¹, Hyon K. Choi⁸, Masato Okada⁹ and Daniel Solomon¹, ¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Department of Cardiovascular Medicine, St. Luke's International Hospital, Tokyo, Japan, ⁴Department of Pulmonary Medicine, St. Luke's International Hospital, Tokyo, Japan, ⁵Department of Gastroenterology, St. Luke's International Hospital, Tokyo, Japan, ⁶Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ⁷Kyorin University School of Medicine, Tokyo, Japan, ⁸MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Understanding longitudinal changes in serum urate (SU) allows for the development of evidence-based interventions for gout. Post-menopausal women, who are at risk of gout,…
Abstract Number: 0330 • ACR Convergence 2025
Prevalence of Radiographic and Symptomatic Osteoarthritis, and Ultrasound Features at the Knee: The Johnston County Health Study
Maya Patel¹, Carolina Alvarez², Todd Schwartz³, Tessa Walker¹, Serena Savage-Guin¹, Jordan Renner¹, Jonathan Samuels⁴, Janice Lin⁵, Minna Kohler⁶, Catherine Bakewell⁷, Yvonne Golightly⁸ and Amanda Nelson¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁴NYU Langone, Rye Brook, NY, ⁵Stanford University, Palo Alto, CA, ⁶Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁷Intermountain Healthcare, Salt Lake City, UT, ⁸University of Nebraska Medical Center, Omaha, NE
Background/Purpose: To report sex and BMI differences among ultrasound (US) features of knee osteoarthritis (KOA), patient-reported symptoms (Ksx), radiographic KOA (rKOA), and symptomatic KOA (sxKOA),…
Abstract Number: 2658 • ACR Convergence 2025
Risk of Immune-Mediated Inflammatory Diseases and Other Safety Outcomes in Patients with T2DM and Obesity Initiating GLP-1 RA: A Propensity Score-Matched Multi-center Study using the TriNetX Global Network
Hsin-Hua Chen and Wen-Cheng Chao, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes mellitus (T2DM) and obesity due to their beneficial metabolic effects. However,…
Abstract Number: 0249 • ACR Convergence 2025
Obesity as a possible confusion factor in the scleroderma pattern
Eva Álvarez Andrés¹, Marta Novella-Navarro², Paloma García de la Peña Lefebvre³, Eugenio de Miguel² and Paz Collado Ramos⁴, ¹Hospital Severo Ochoa de Madrid, Madrid, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³Facultad ciencias de la Salud HM de la UCJC, Madrid, Spain, ⁴Department of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain,, MADRID, Madrid, Spain
Background/Purpose: The 2023 EULAR criteria for systemic sclerosis reaffirm the diagnostic value of nailfold videocapillaroscopy (NVC), particularly the presence of giant capillaries and capillary loss…
Abstract Number: 2604 • ACR Convergence 2025
Cross-Sectional Relationship Between Sarcopenic Obesity and Knee Osteoarthritis: The Johnston County Osteoarthritis Project
David Werner¹, Carolina Alvarez², John Batsis³, Reece Blay⁴, Laura Bilek⁵, Amanda Nelson³ and Yvonne Golightly⁵, ¹University of Nebraska Medical Center, Mason, OH, ²University of North Carolina at Chapel Hill, Miami, FL, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴University of Nebraska Medical Center, Council Bluffs, IA, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Current consensus for defining sarcopenia (loss of muscle mass and strength with aging) and sarcopenic obesity (SO, sarcopenia with obesity) suggests combining measures of…
Abstract Number: 0581 • ACR Convergence 2025
Effects of Apremilast on Body Mass Index, Weight, and HbA1c as Cardiometabolic Outcomes in Patients With Early Oligoarticular Psoriatic Arthritis in the FOREMOST Study
Philip J. Mease¹, Álvaro González Cantero², Jennifer Soung³, April Armstrong⁴, Joseph F Merola⁵, Fabian Proft⁶, Laure Gossec⁷, Dafna D. Gladman⁸, Laura Coates⁹, Lichen Teng¹⁰, Jimena Vázquez¹¹, Cynthia Deignan¹² and Arthur Kavanaugh¹³, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Dermatology, Ramón y Cajal University Hospital, Madrid, Spain, ³Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ⁴University of California Los Angeles, Los Angeles, ⁵Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁶Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷Sorbonne Université, Pitié Salpêtrière Hospital, Paris, France, ⁸Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ¹⁰Amgen Inc., Thousand Oaks, ¹¹Amgen Inc., Thousand Oaks, CA, ¹²Amgen, Inc., Agoura Hills, CA, ¹³University of California, San Diego, School of Medicine, San Diego, CA
Background/Purpose: The prevalence of cardiometabolic diseases, including obesity and diabetes, is higher in patients with psoriatic arthritis (PsA) than those without PsA.1,2 Metabolic syndrome is…
Abstract Number: 2392 • ACR Convergence 2025
Does Obesity Influence Disease Activity and Biomarkers in Systemic Lupus Erythematosus Patients?: A Retrospective Study
Daniyal Nadeem¹, Anusheh Ali², Shravya Balmuri², Megan Mattison³, Upasana Agrawal⁴, Alexandra Zamora-Smith⁵, Karan Sachdeva⁶, Teresa leeth¹, Robert Quinet⁷, William Davis⁸, Jerald Zakem⁹, Chandana Keshavamurthy¹⁰, Xin Zhang¹¹, Sarwat Umer¹² and Samina Hayat¹³, ¹Louisiana State University Health Science, Shreveport, LA, ²Louisiana State University, Shreveport, LA, ³Louisiana State University- Shreveport, Shreveport, LA, ⁴Louisiana State University Health Sciences, Shreveport, Shreveport, LA, ⁵LSU Health Science Center in Shreveport, Shreveport, LA, ⁶Louisiana state university health shreveport, shreveport, ⁷Department of Rheumatology, Ochsner Health, New Orleans, LA, ⁸Ochsner Health System, New Orleans, LA, ⁹Ochsner Health Systems, Metairie, LA, ¹⁰banner university medical center, phoenix, AZ, ¹¹Ochsner Medical Center, New Orleans, LA, ¹²LSUHSC Shreveport, Shreveport, LA, ¹³Louisiana state university Shreveport, Shreveport, LA
Background/Purpose: Obesity, a prevalent condition, is known to exacerbate inflammation and could potentially influence the progression and severity of autoimmune diseases like Systemic lupus erythematosus…
Abstract Number: 1508 • ACR Convergence 2025
Dissecting the Role of T Cell Subsets and Complements in Lupus Pathogenesis in Systemic Lupus Erythematosus Patients with Obesity
Sheila Serin¹, Megan Schluentz¹, Chandana Keshavamurthy¹, Alexandra Reese¹, Sneha Centala¹, Bettina Boone¹, Samantha Ahrens², William Davis³, Robert Quinet¹, Jerald Zakem⁴, Samina Hayat⁵, Sarwat Umer⁶, Teresa leeth⁷, Daniyal Nadeem⁷ and Xin Zhang⁸, ¹Department of Rheumatology, Ochsner Health, New Orleans, LA, ²Multi-specialty Clinical Research, Ochsner Health, New Orleans, LA, ³Ochsner Health System, New Orleans, LA, ⁴Ochsner Health Systems, Metairie, LA, ⁵Louisiana state university Shreveport, Shreveport, LA, ⁶LSUHSC Shreveport, Shreveport, LA, ⁷Louisiana State University Health Science, Shreveport, LA, ⁸Ochsner Medical Center, New Orleans, LA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by systemic inflammation, autoantibody production, and multiorgan involvement. Although genetic, hormonal, and environmental factors…

1
2
3
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].